$LLY

Hakim Anat (EVP, GC & Secretary) sold 5,000 indirectly-held shares of ELI LILLY & Co (LLY) at $1402.52 ($7.01M total) on 2026-11-02 under a Rule 10b5-1 trading plan.

Microsoft loses CVP Mazhar Mohammed to AWS, gains Chad Thompson from Alteryx. Amazon appoints Gail Carpenter as CFO of Global Entertainment and Advertising. Lila Bio, a biotech startup, names Kimberly Ma as CDO. BECU appoints Geoffrey Fonga as VP of AI transformation. RevealDx, developing AI for cancer detection, adds two leaders. LogicGate, a software company, names two new leaders. Known, an AI accountability infrastructure company, appoints Edna Conway to its advisory council.

Eli Lilly (LLY) hit a record high, raising its 2026 revenue forecast to $91-$92B, lifting its market value to $1.1T. Macro investor Jordi Visser predicts Lilly will become the world's most valuable company due to steady healthcare spending and AI investment. Analysts expect Nvidia's (NVDA) earnings per share to quadruple in three years, making Lilly's potential surpass a significant challenge.

Eli Lilly reported a 39% year-over-year revenue increase to $24.4B in Q3, driven by obesity drugs Mounjaro and Zepbound. Analysts project strong future growth, with RBC Capital Markets raising its 2026 revenue forecast to $91.2B. Lilly is diversifying its pipeline with acquisitions and investments, including psychedelic-based treatments and cancer therapies, but has faced setbacks in gene therapy and other programs.

Eli Lilly reported Q3 revenue of $24.40B, up 38.6%, driven by tirzepatide. CEO highlighted pipeline diversification. Shares up 30.44% YTD. Analysts target $1,333.72, but 2027 estimates suggest $1,700 is possible. Growth in oncology, immunology, and neuroscience cited. EPS beat estimates for five straight quarters.

Eli Lilly (LLY) stock rose 22% in October, driven by strong Q3 earnings, higher revenue guidance, and positive clinical trial results for retatrutide. Revenue increased 39% to $24.4B, with Mounjaro and Zepbound contributing significantly. Lilly raised 2026 revenue guidance to $91B-$92B. Goldman Sachs set a $1,413 price target. Novo Nordisk (NVO) faces competition from retatrutide, which outperformed Ozempic in a Phase 3 trial.

ETFs focused on global pharmaceutical companies, particularly those in obesity treatment, saw strong returns amid tech and semiconductor stock declines. Eli Lilly reported Q3 revenue of $24.4B, up 38.6% YoY, driven by obesity drugs Mounjaro and Zepbound. Novo Nordisk and other Big Pharma stocks also rose, benefiting from defensive characteristics and upcoming clinical trial announcements.

Eli Lilly (NYSE:LLY) hit a new high of $1,400 after reporting Q3 revenue of $24.4B, up 39% YoY. The company raised full-year sales guidance to $91-92B but slightly lowered EPS guidance. The stock's 45x earnings multiple raises concerns about future growth being priced in, despite its strong performance driven by GLP-1 drugs.

Viatris (VTRS) and Eli Lilly (LLY) raised 2026 sales forecasts. Lilly increased its revenue forecast to $91.5B, while Viatris raised its forecast to $14.75B. Lilly's growth is driven by Mounjaro and Zepbound, while Viatris focuses on generics and potential blockbuster drugs. Lilly has higher margins and lower debt, but Viatris trades at a lower valuation.

Anthropic spent $9.5B on R&D in Q3, surpassing Microsoft's $9.05B, according to its IPO prospectus. Only Alphabet, Meta, Apple, and Samsung reported higher R&D. Anthropic's R&D is primarily compute and infrastructure costs, with significant cloud service provider spending. The company has $131.8B in cash and $895.4B in purchase commitments.